Literature DB >> 25596843

Changes in the expression of genes related to neuroinflammation over the course of sporadic Alzheimer's disease progression: CX3CL1, TREM2, and PPARγ.

S Strobel1, E Grünblatt, P Riederer, H Heinsen, T Arzberger, S Al-Sarraj, C Troakes, I Ferrer, Camelia Maria Monoranu.   

Abstract

The role of neuroinflammation in the pathogenesis of neurodegenerative diseases has become more evident in recent years. Research on the etiology and pathogenesis of sporadic Alzheimer's disease (AD) has focused on the role of chemokines such as CX3CL1, on the triggering receptors expressed by myeloid cells (TREMs), especially TREM2, and on the transcription factor/nuclear hormone receptor peroxisome proliferator-activated receptor gamma (PPARγ). Here we analyzed the expression levels of CX3CL1, TREM2, and PPARγ in tissue homogenates from human brain regions that have different degrees of vulnerability to neuropathological AD-related changes to obtain insights into the pathogenesis and progression of AD. We found that CX3CL1 and TREM2, two genes related to neuroinflammation, are more highly expressed in brain regions with pronounced vulnerability to AD-related changes, such as the hippocampus, and that the expression levels reflect the course of the disease, whereas regions with low vulnerability to AD, seemed generally less affected by neuroinflammation. Furthermore, our results support previous findings of significantly higher CX3CL1 plasma levels in patients with mild to moderate AD than in patients with severe AD. Thus, CX3CL1 should be considered as promising additional marker for the early diagnosis of AD and underlines once more, the involvement of the neuroinflammation in the pathogenesis of this neurodegenerative disease.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25596843     DOI: 10.1007/s00702-015-1369-5

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  35 in total

1.  Morphological changes of the human purkinje cells and deposition of neuritic plaques and neurofibrillary tangles on the cerebellar cortex of Alzheimer's disease.

Authors:  Ioannis A Mavroudis; Dimitrios F Fotiou; Luc F Adipepe; Marina G Manani; Samuel D Njau; Dimitrios Psaroulis; Vasiliki G Costa; Stavros J Baloyannis
Journal:  Am J Alzheimers Dis Other Demen       Date:  2010-09-23       Impact factor: 2.035

Review 2.  Nuclear receptors as therapeutic targets for Alzheimer's disease.

Authors:  Shweta Mandrekar-Colucci; Gary E Landreth
Journal:  Expert Opin Ther Targets       Date:  2011-07-01       Impact factor: 6.902

3.  Mechanisms underlying the rapid peroxisome proliferator-activated receptor-γ-mediated amyloid clearance and reversal of cognitive deficits in a murine model of Alzheimer's disease.

Authors:  Shweta Mandrekar-Colucci; J Colleen Karlo; Gary E Landreth
Journal:  J Neurosci       Date:  2012-07-25       Impact factor: 6.167

Review 4.  What happens to microglial TREM2 in Alzheimer's disease: Immunoregulatory turned into immunopathogenic?

Authors:  L-F Lue; C Schmitz; D G Walker
Journal:  Neuroscience       Date:  2014-10-02       Impact factor: 3.590

5.  Correlations between cortical and subcortical tau pathology.

Authors:  J Attems; A Thomas; K Jellinger
Journal:  Neuropathol Appl Neurobiol       Date:  2012-10       Impact factor: 8.090

6.  Brainstem: neglected locus in neurodegenerative diseases.

Authors:  Lea Tenenholz Grinberg; Udo Rueb; Helmut Heinsen
Journal:  Front Neurol       Date:  2011-07-11       Impact factor: 4.003

7.  Insights into TREM2 biology by network analysis of human brain gene expression data.

Authors:  Paola Forabosco; Adaikalavan Ramasamy; Daniah Trabzuni; Robert Walker; Colin Smith; Jose Bras; Adam P Levine; John Hardy; Jennifer M Pocock; Rita Guerreiro; Michael E Weale; Mina Ryten
Journal:  Neurobiol Aging       Date:  2013-07-12       Impact factor: 4.673

Review 8.  Neuron-glia crosstalk in health and disease: fractalkine and CX3CR1 take centre stage.

Authors:  Graham K Sheridan; Keith J Murphy
Journal:  Open Biol       Date:  2013-12-18       Impact factor: 6.411

Review 9.  Heterogeneity of microglial activation in the innate immune response in the brain.

Authors:  Carol A Colton
Journal:  J Neuroimmune Pharmacol       Date:  2009-08-05       Impact factor: 4.147

Review 10.  Late-Onset Alzheimer's Disease Genes and the Potentially Implicated Pathways.

Authors:  Samantha L Rosenthal; M Ilyas Kamboh
Journal:  Curr Genet Med Rep       Date:  2014-03-22
View more
  23 in total

Review 1.  Resistance, vulnerability and resilience: A review of the cognitive cerebellum in aging and neurodegenerative diseases.

Authors:  Katharine J Liang; Erik S Carlson
Journal:  Neurobiol Learn Mem       Date:  2019-01-07       Impact factor: 2.877

2.  Peripheral sTREM2-Related Inflammatory Activity Alterations in Early-Stage Alzheimer's Disease.

Authors:  Grace E Weber; Maria Khrestian; Elizabeth D Tuason; Yvonne Shao; Jagan Pillai; Stephen Rao; Hao Feng; Yadi Zhou; Feixiong Cheng; Tara M DeSilva; Shaun Stauffer; James B Leverenz; Lynn M Bekris
Journal:  J Immunol       Date:  2022-05-06       Impact factor: 5.426

3.  Convergent Genetic and Expression Datasets Highlight TREM2 in Parkinson's Disease Susceptibility.

Authors:  Guiyou Liu; Yongquan Liu; Qinghua Jiang; Yongshuai Jiang; Rennan Feng; Liangcai Zhang; Zugen Chen; Keshen Li; Jiafeng Liu
Journal:  Mol Neurobiol       Date:  2015-09-14       Impact factor: 5.590

Review 4.  Systematic Review of the Neurobiological Relevance of Chemokines to Psychiatric Disorders.

Authors:  Michael J Stuart; Gaurav Singhal; Bernhard T Baune
Journal:  Front Cell Neurosci       Date:  2015-09-10       Impact factor: 5.505

5.  TREM2 upregulation correlates with 5-hydroxymethycytosine enrichment in Alzheimer's disease hippocampus.

Authors:  Naiara Celarain; Javier Sánchez-Ruiz de Gordoa; María Victoria Zelaya; Miren Roldán; Rosa Larumbe; Laura Pulido; Carmen Echavarri; Maite Mendioroz
Journal:  Clin Epigenetics       Date:  2016-04-05       Impact factor: 6.551

Review 6.  Role of Atypical Chemokine Receptors in Microglial Activation and Polarization.

Authors:  Valentina Salvi; Francesca Sozio; Silvano Sozzani; Annalisa Del Prete
Journal:  Front Aging Neurosci       Date:  2017-05-26       Impact factor: 5.750

7.  Icariside II Effectively Reduces Spatial Learning and Memory Impairments in Alzheimer's Disease Model Mice Targeting Beta-Amyloid Production.

Authors:  Lingli Yan; Yuanyuan Deng; Jianmei Gao; Yuangui Liu; Fei Li; Jingshan Shi; Qihai Gong
Journal:  Front Pharmacol       Date:  2017-03-08       Impact factor: 5.810

8.  Differential chemokine expression under the control of peripheral blood mononuclear cells issued from Alzheimer's patients in a human blood brain barrier model.

Authors:  Julie Vérité; Guylène Page; Marc Paccalin; Adrien Julian; Thierry Janet
Journal:  PLoS One       Date:  2018-08-09       Impact factor: 3.240

Review 9.  CX3CL1/CX3CR1 in Alzheimer's Disease: A Target for Neuroprotection.

Authors:  Peiqing Chen; Wenjuan Zhao; Yanjie Guo; Juan Xu; Ming Yin
Journal:  Biomed Res Int       Date:  2016-06-27       Impact factor: 3.411

Review 10.  TREM2 in Neurodegenerative Diseases.

Authors:  Taylor R Jay; Victoria E von Saucken; Gary E Landreth
Journal:  Mol Neurodegener       Date:  2017-08-02       Impact factor: 14.195

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.